deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 30-arm NCT02687373

Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya

Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months Through 9 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age De-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy

Sponsor: Centers for Disease Control and Prevention

Conditions Malaria
Updated 12 times since 2017 Last updated: Apr 18, 2019 Started: Jul 21, 2016 Primary completion: Aug 31, 2018 Completion: Aug 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Malaria and is currently completed. Centers for Disease Control and Prevention leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshotRecruiting~Dec 2017 – ~May 2018 · 5 months · monthly snapshotActive Not Recruiting~May 2018 – ~Jun 2018 · 31 days · monthly snapshotActive Not Recruiting~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotActive Not Recruiting~Nov 2018 – ~May 2019 · 6 months · monthly snapshotActive Not Recruiting~May 2019 – ~Sep 2019 · 4 months · monthly snapshotCompleted~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshotCompleted~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshotCompleted~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

12 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Sep 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

Show 7 earlier versions
  1. May 2019 — Sep 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not RecruitingCompleted

  2. Nov 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Dec 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: RecruitingActive Not Recruiting

  6. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centers for Disease Control and Prevention
  • Kenya Medical Research Institute
  • National Institutes of Health (NIH)
  • Sanaria Inc.
  • University of Maryland
Data source: Sanaria Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations